Recurrence Data for Narrow Band Imaging™ (NBI™) Technology Show Value in the Fight Against Non-Muscle Invasive Bladder Cancer
CENTER VALLEY, Pa., April 24, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today data showing that the use of Narrow Band Imaging (NBI) technology with patients with non-muscle invasive bladder cancer (NMIBC) led to 37% less likelihood of recurrence over 12-35 months.1
- As reported by the American Cancer Society, bladder cancer has one of the highest recurrence rates.2 Additionally, "recurrence and progression to muscle-invasive bladder cancer (MIBC) is highly variable, depending on tumor classification and grade at diagnosis.
- For example, in patients diagnosed with low-grade noninvasive urothelial carcinoma (Ta), recurrence rates range from 30% to 60% at 5 years; however, the risk of progression to MIBC is ≤5%.
- In contrast, patients with high-grade urothelial carcinoma invading into the lamina propria (T1) have progression rates of 30% to 70%."
- NBI technology will also be available for demo at the Olympus booth at the American Urological Association (AUA) conference, May 3-6, 2024, in San Antonio, TX.